Search Login Register

fondaparinux (Arixtra) Summary

Description: synthetic analog of the pentasaccharide sequence that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; used for the for prevention of venous thromboembolism after surgery

Also Known As: Arixtra; Quixidar; Sanofi Synthelabo brand of fondaparinux sodium; Sanofi brand of fondaparinux sodium; fondaparinux sodium

Networked: 649 relevant articles (74 outcomes, 167 trials/studies) for this Drug

Key Diseases for which fondaparinux is Relevant

  1. Venous Thromboembolism : 28 outcomes 46 studies in 183 results
  2. Hemorrhage : 19 outcomes 41 studies in 186 results
  3. Acute Coronary Syndrome : 9 outcomes 31 studies in 74 results
  4. Thrombosis (Thrombus) : 9 outcomes 15 studies in 97 results
  5. Venous Thrombosis (Deep-Vein Thrombosis) : 7 outcomes 15 studies in 80 results
Show All >>

Drugs Related to fondaparinux

  1. Enoxaparin (Lovenox)
  2. Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
  3. Heparin (Liquaemin)
  4. Factor Xa (Coagulation Factor Xa)
  5. Vitamin K
  6. fondaparinux (Arixtra)
  7. Aspirin (Acetylsalicylic Acid)
  8. Hirudins
  9. Anticoagulants
  10. bivalirudin (Angiomax)
Show All >>

Therapies Related to fondaparinux

  1. Catheters
  2. Thrombolytic Therapy
  3. Transplants (Transplant)
  4. Coronary Artery Bypass (Coronary Artery Bypass Surgery)
  5. Subcutaneous Injections
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.